Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

venetoclax 47Cyclophosphamide 43Specimen Handling 42Cytarabine 41fludarabine 32Biopsy 31Azacitidine 25Rituximab 20Methotrexate 17fludarabine phosphate 16blinatumomab 16Vincristine 15Daunorubicin 15Dexamethasone 14ibrutinib 13Whole-Body Irradiation 13Prednisone 13Magnetic Resonance Spectroscopy 13Injections 13obinutuzumab 11merphos 11Mercaptopurine 11Filgrastim 11Calcium Dobesilate 11asciminib 10X-Rays 10Stem Cell Transplantation 10Mycophenolic Acid 10Doxorubicin 10decitabine and cedazuridine drug combination 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
etoposide phosphate × Other hematologic neoplasm × 30 days × Clear all
NCT02583893 2026-05-29

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

Thomas Jefferson University

Phase 2 Completed
39 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡